Considering the increasing clinical benefits of targeting immune checkpoints as a combination therapy (59, 60), we enrolled several immune checkpoint molecules that have been examined in clinical trials or clinical situations into correlation analysis to assess their relationship with NR2F6 in glioma samples using both TCGA and CGGA datasets (61, 62). The gene discussed is NR2F6; the disease is central nervous system cancer.